Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Post by cool888on Jul 26, 2021 4:13pm
127 Views
Post# 33605635

House committee seeks more from FDA on inspection backlog

House committee seeks more from FDA on inspection backlog
House committee seeks more from FDA on inspection backlog, when to restart work on foreign sites

Zachary Brennan
Senior Editor

House Energy & Commerce committee leaders are raising fresh questions about the FDA’s ability to conduct foreign manufacturing site inspections and bring down its growing backlog.
 
“While we understand that the emergence of COVID-19 required the agency to suspend in-person inspection activities temporarily, we remain concerned that more than one year into the pandemic, the strategy for resuming all inspections and addressing the backlog of delayed inspections remains unclear,” E&C chair Frank Pallone (D-NJ) and a group of five other bipartisan leaders of the committee wrote to FDA acting commissioner Janet Woodcock.
 
The letter follows Woodcock’s announcement last Monday that, for the first time since March 2020, the FDA’s inspections of US-based biopharma sites have returned to normal.
 
As Woodcock struck a more optimistic tone in that announcement, the House representatives note that foreign facilities inspected by US-based staff are only subject to mission-critical inspections, and while the agency has alternative methods to inspect sites remotely, “it is largely unclear for which types of inspections, if any, FDA can appropriately use these alternatives as a full substitute for an in-person inspection,” the representatives wrote.
 
For example, remote evaluations cannot satisfy the statutory requirement for surveillance inspections, as those must be either onsite or conducted by the FDA’s foreign counterparts. The agency said it postponed nearly 8,000 non-mission-critical surveillance inspections in 2020 due to the pandemic.
 
“We are also concerned that we have not yet seen the full impact of delayed inspections, particularly in the case of preapproval inspections (PAIs). PAIs may occur well in advance of targeted dates for drug approval decisions. Therefore, drug applications and approvals may be affected in the future if inspections continue to be postponed, possibly delaying patient access to needed medications,” the letter says.
 
According to a report from the FDA in May, an estimated 68 applications (including 48 for different drugs) have already been delayed due to the FDA’s inability to conduct pre-approval, pre-market, or pre-license inspections as of March.
 
The lawmakers also questioned Woodcock, seeking responses by Aug. 5 on whether the agency has an analysis to determine how delayed inspections may impact the agency’s ability to make drug approval decisions in the coming months and years.
<< Previous
Bullboard Posts
Next >>